Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion type Assertion NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_head.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_provenance.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion evidence source_evidence_literature NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_provenance.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion SIO_000772 21245420 NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_provenance.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion wasDerivedFrom befree-20140225 NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_provenance.
- NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_assertion wasGeneratedBy ECO_0000203 NP350682.RAZ4by4WRS8W22p3u5lG_wJgTaAq6zMXc2J-Zs8HJI-7E130_provenance.